

# Q BioMed Inc.

09:25 11 Aug 2020

## Q BioMed Inc. launches program to bring metastatic bone pain drug Strontium89 to the EU and elsewhere

Q BioMed Inc (OTCQB:QBIO) has launched a Named Patient Program (NPP) to bring its non-opioid bone metastasis pain drug Strontium89 to patients around the world starting in September, the company announced on Tuesday.

Strontium89 is FDA-approved for the treatment of painful skeletal metastases caused by cancer, regardless of the type of tumor. Common cancers that metastasize to the bone include prostate, breast, lung and others.

The NPP allows Strontium89 to be provided to patients internationally without needing additional regulatory approval in their countries. It will be facilitated by Caligor Coghlan Pharma Services, a global pharmaceuticals company based in Texas.

### READ: Q Biomed to scale-up production of potential liver cancer chemotherapeutic Utroside-B as it gears up for IND filing

"We are very happy that Strontium89 is once again available worldwide, and that physicians have the ability to prescribe a safe, effective and non-opioid treatment to their be metastasis pain patients regardless of their primary tumor type and notably beyond prostate cancer," Q BioMed CEO Denis Corin said in a statement. "We are actively working to ensure that Strontium89 is accessible to patients everywhere and to extend its relevance and use thorough additional clinical study."

Strontium89 is administered intravenously once every three months and can reduce or even eliminate the need for opioid analgesics, the company said, delivering pain relief for 2-5 months in most patients.

In several multicenter, placebo-controlled trials of cancer patients with pain from bone metastases, relief occurred in more patients treated with a single injection of Strontium89 than in patients treated with an injection of placebo.

Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter @andrew\_kessel

**Price:** 1.1

**Market Cap:** \$24.82 m

#### 1 Year Share Price Graph



February 2020 August 2020 February 2021

#### Share Information

**Code:** QBIO

**Listing:** OTCQB

52 week	High	Low
	3.12	0.9001

**Sector:** Medical technology & services

**Website:** [qbiomed.com](http://qbiomed.com)

#### Company Synopsis:

Q BioMed Inc. (OTCQB: QBIO) is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued and under-appreciated biomedical assets. QBIO is dedicated to providing these target assets, the strategic resources, developmental support, and expansion capital to ensure they meet their potential.

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).